GSK2878175

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Hepatitis C, Chronic

Phase 1

A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects

CompletedNCT01879462

GlaxoSmithKlineHepatitis C, Chronic

Start: 2013-06-14End: 2014-01-10Updated: 2018-07-24

Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.

CompletedNCT02014571

GlaxoSmithKlineHepatitis C, Chronic

Start: 2013-12-26End: 2015-01-15Updated: 2018-07-24